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ABSTRACT
Although one million new breast cancer cases arise each year worldwide, therapies to
treat the disease are limited. Conventional treatments including the chemotherapeutic
agent, Tamoxifen, have had only limited success, often showing uncomfortable side
effects. Our group has proposed a new scheme for a rational drug design. This scheme
utilizes recent findings on the mechanism of cisplatin, the drug found to cure in excess of
93% of all testicular cancer cases. Cisplatin forms DNA adducts that are toxic. The
toxicity of these adducts is enhanced by the recruitment of proteins that bind to the
adducts and impede adduct repair. This thesis was an attempt to duplicate this "repair
shielding" mechanism with another cytotoxin. Specifically, this toxin will be
programmed to kill breast cancer cells. Breast cancer cells often overexpress the estrogen
receptor protein. By synthesizing a drug that not only binds and damages the DNA but
also binds the abundant proteins in the cells, thereby blocking the damaged site from
DNA repair proteins, a selective treatment of cancer cells can be achieved.
In this study, the human estrogen receptor (hER) and the ligand binding domain of the
hER genes were cloned into baculovirus expression vectors, establishing a system where
a large quantity of the proteins can be expressed. The proteins expressed in insect cells
were purified in one step, using the FLAG-epitope, yielding homogeneous proteins. The
proteins were tested for binding to p-estradiol and were confirmed to be functional in
ligand binding. They were also tested for their ability to bind the novel drugs synthesized
to bind both the protein and the DNA. It was found that the ligand binding domain of the
hER was capable of binding the drugs adducted to the DNA. In an effort to elucidate the
mechanism of the protein-drug-DNA complex formation, an association experiment was
carried out, which showed that the drug more readily bound to the protein than to DNA.
However, a significant amount of the drug-protein complex still bound the DNA, if the
ratio of the protein to the drug did not exceed 1.5.
Thesis Supervisor: John M. Essigmann
Title: Professor of Chemistry and Toxicology
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Chapter I. Introduction and Background
Research objectives
Each year, one million new cases of breast cancer are reported in the United
States and approximately 400,000 people die from the disease. Most anti-cancer
treatments available today have limited success. Many of the chemotherapeutic agents
are not tumor-selective, causing many side effects during the treatment.
Chemotherapeutic agents often kill dividing cells by damaging DNA. These drugs are
not only lethal to cancer cells, but also to non-cancerous cells, causing many side effects.
Moreover, in most cases, these treatments extend life, but do not completely eradicate
cancer. One exception is cisplatin, which cures >93% of testicular cancers. Cisplatin
displays its toxicity by binding to and damaging DNA (1). Proteins may bind to the drug
adducts (2,3), blocking the lesion from being repaired by DNA repair enzymes. This
information has become the foundation of an effort to design drugs that selectively kill
tumor cells.
If a drug can form adducts on DNA and also can bind to a tumor tissue specific
protein, it would result in an unrepairable lesion. Such drug would give tumor specificity
during chemotherapy. The target tumor chosen for this was breast cancer cells, which
often overexpress estrogen receptors.
Compounds containing estradiol-like moiety were synthesized and were tested in
cell lines overexpressing estrogen receptor. However, as the research expanded, the need
for homogeneous human estrogen receptor in the laboratory increased. The calf uterus
cell extract as the source of the protein was inadequate, because of the low concentration
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of the estrogen receptor among countless other cellular proteins in the extract. The main
objective of this study was to develop and optimize the protein expression system that
would produce a large quantity of the protein competent to bind ligands. The resulting
purified protein was used to test the ability of the ER to bind the mechanism-based drugs
synthesized in the laboratory, an important step in identifying potential new drugs.
This dissertation will be organized in the following manner:
Chapter I. Introduction and Background will focus on the background of the project
including the features of the baculovirus expression.
Chapter II. Material and Methods will elaborate the details of the experiments.
Chapter III. Results will present the outcomes of the experiments.
Chapter IV. Discussion will summarize the conclusions that could be made from the
experimental data.
Breast cancer and conventional therapy
Breast cancer is the number one cause of cancer death in women in the United
States, with 45,000 women dying of the disease in 1998 and one million new cases of the
disease expected to be reported around the world each year. Despite recent increases in
awareness of the importance of early detection by regular mammography and self-
examination has decreased the number of deaths, the disease continues to be a formidable
public health problem.
The conventional course of action to treat breast cancer consists of surgical
removal of the tumor, followed by radiation and chemotherapy. A long-term regimen of
Tamoxifen, which acts to keep the tumor in remission, follows the combined treatment.
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Although this multi-staged treatment has shown to decrease the breast cancer mortality, it
is not without an expense. The initial chemotherapy gives rise to many widely known
adverse side effects, such as bone marrow decimation, nausea and hair loss. It has been
reported that Tamoxifen, although it is shown to decrease the tumor recurrence by 45%,
increases the risk of endometrial cancer in women who take the drug. Thus, it is of
essence that a new approach to the treatment of the cancer is explored. The laboratory
has been working on designing drugs that would selectively kill tumor, therefore
eliminating such side effects during chemotherapy.
Tumor selective genotoxins
The intellectual basis for the project of designing tumor selective anti-cancer
chemotherapeutic agent stemmed from the study of the biochemical mechanisms of
cisplatin (cis-diamminedichloroplatinum(II)). Regimens including cisplatin are widely
used for the treatment of testicular cancer and have been shown to cure almost all of the
patients treated with the drug (4), an impressive effect unseen in most other anti-cancer
agents. Despite continuing efforts to elucidate the mechanisms of action of cisplatin, its
biochemical workings at molecular level are still not fully understood. However, it has
been shown that cisplatin kills cells, in part, by damaging the DNA of the cells (1).
Subsequently, a group of proteins was identified that binds the DNA adduct formed by
cisplatin (2,3). These proteins show a selective affinity for the DNA adducts (3),
suggesting that the proteins play a role in cisplatin toxicity. One of the models suggested
to explain this phenomenon was the "repair shielding" theory, which proposed that the
binding of these proteins to the drug adduct physically blocks the damaged site from
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DNA repair proteins thereby heightening the potency of the drug. It is this model that the
design scheme of novel drugs selective toward cancer cells is based.
Many cancer cells are known to express proteins specific to the tissue type or
cancer. By synthesizing compounds that recognize the tumor specific protein and also
damage DNA, tumor selectivity can be achieved (Figure 1). These drugs, if
administered into non-cancerous cells, will damage DNA, but the lesions will be readily
repaired by the DNA repair machinery due to the absence of the proteins. The system
chosen to test this approach was breast cancer cells. Many breast cancers overexpress
estrogen receptor, providing a good target for the project. The compounds are composed
of two domains, the DNA-reactive domain, or "warhead," and the protein recognition
domain. The two domains are connected by a linker. The functional group selected for
the warhead was a nitrogen mustard, which was known historically to form adducts and
damage DNA. The protein recognition group was derived from, or functionally mimics,
estradiol, the natural ligand of the tumor specific protein. Figure 2 shows the structures
and the names of the compounds synthesized according to this scheme and used in
experiments described in this dissertation.
The theory behind the scheme was confirmed in the study where 2PI-C6NC2
(Figure 2, B) was tested for its toxicity in ER(+) and ER(-) cells. The drug showed
increased toxicity in ER-expressing cancer cells (5). It was calculated that
approximately 20-25% of the DNA adducts would associate with the ER in vivo, thereby
blocking the repair. It has since been demonstrated, that the DNA lesions associated with
ER were repaired slower than the lesions formed in ER(-) cell line (Croy and Essigmann,
unpublished data).
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Estrogen receptor
The target protein for the tumor specific genotoxins developed in the laboratory is
the estrogen receptor, a protein belonging to the nuclear hormone receptor superfamily.
These proteins act as transcriptional regulators, which bind to specific DNA elements and
activate transcription in response to the binding of a steroid hormone (6). The ER is a
67kDa protein found in a wide variety of species and is involved in the regulation of gene
expression in tissues of female sex organs (7). It has been reported that more than 50%
of human breast cancers overexpress the ER.
The human ER (hER) cDNA was cloned and completely sequenced by Green and
the co-workers in 1986 (7). The hER cDNA is 1.8kb long and codes for a protein with
595 amino acid residues. Analogous to the typical structural scheme of the nuclear
receptors, the ER is divided into 6 domains, designated A through F, classified according
to the functions of each region (8). The N-terminal domains A and B contain the
constitutive transcriptional activation function, AF-1. The C domain is the DNA binding
domain (DBD), which shows a high degree of homology to the DNA binding domains of
other nuclear hormone receptors (8). The D domain is designated as the "hinge" domain.
The E domain is the ligand binding domain (LBD), which recognizes the hormone; the
LBD, upon binding ligand, transforms the receptor to a transcriptionally active state (9).
Finally, the F domain is the carboxy-terminal domain, which has variable homology
among the receptor proteins.
The hormone ligand, as mentioned earlier, is estradiol (Figure 2A). Estradiol
binds to ER tightly with the Kd of 0.35 nM (10). When estradiol is bound to the ligand
binding domain of the ER, two molecules of the protein form a homodimer. This
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complex, when bound to a specific region of the promoter, activates the transcription of
gene connected to the promoter (11).
Figure 3A is a representation of the ER-LBD homodimer containing two
molecules of estradiol in its binding domain. It was rendered from the crystal structure
coordinates reported by Tanenbaum and co-workers (12). The structure of the protein
was solved in complex with estradiol, giving insights into the interactions between the
receptor and the ligand at the molecular level. Figure 3B illustrates the interactions in
detail. The ligand is held in the binding cavity by a number of hydrogen bonds with the
amino acid residues and water molecules. The D-ring hydroxyl group of the estradiol
forms a hydrogen bond with His5 11. The phenyl hydroxyl group of the hormone makes
a hydrogen bond with the carboxylate of Glu353 and a water-mediated hydrogen bond
supported by Arg394. The same three residues were implicated as being important for
ligand binding in an earlier study (13), confirming the structure of the binding cavity of
the protein.
Figure 4 shows the ER-LBD binding E2-C6NC2 (Figure 2D), one of the drugs
designed according to the strategy described earlier in this chapter. The drug molecule
was docked into the protein rendered from the crystal coordinates reported by
Tanenbaum et al. (12), and the complex was energy-minimized in water using the
molecular modeling software, Insight II (Biosym). Since the protein recognition domain
of the drug is estradiol, it is hypothesized that the interactions in the binding cavity of the
protein would closely resemble the interactions between the protein and estradiol.
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Baculovirus expression system
In the past, the estrogen receptor was obtained for work in this laboratory from a
calf uterus cell extract. In addition to the unpleasantness of the preparation, the cell
extract was not an adequate source of the protein, because it yielded only limited quantity
of the protein. Also, because the extract contains other cellular proteins, the possibility of
proteins other than estrogen receptor acting on the system could not be eliminated.
Lastly, only bovine estrogen receptor, not human estrogen receptor, could be obtained
from the preparation. Thus, there was a great need for a recombinant human protein
expression system.
The baculovirus expression system has become widely used for recombinant
eukaryotic protein production because of its ability to produce large quantities of
biologically active eukaryotic proteins (14). By placing the gene coding for the protein
of interest under the control of a strong baculoviral promoter, a high expression level of
the protein can be achieved in insect cells. The proteins expressed in the cells can be
purified using many protein purification tools commercially available, including the
products developed for the purification of FLAG® epitope (Sigma) tagged proteins. In
this section, a general overview and the features of the baculovirus expression system
will be discussed. Also, a brief description of the isolation of the recombinant virus will
be introduced.
The baculovirus vector uses the highly expressed and regulated Autographa
californica nuclear polyhedrosis virus (AcMNPV) polyhedrin promoter (15) modified for
the insertion of foreign genes. Insect cells provide an eukaryotic environment for
posttranslational modification and folding which may be essential for producing
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biologically active proteins (16). Posttranslational modifications of the gene products
achieved by baculovirus expression systems closely resemble glycosylation, fatty acid
acylation and phosphorylation normally present in their native forms (17). Baculoviruses
infect insects and insect cells and they are not pathogenic to vertebrates or plants (18),
making them safe and easy to handle. The stability of the recombinant viruses allows a
long-term storage of the viruses.
The structure and the life cycle of the baculovirus makes it well suited for the use
in protein expression. AcMNPV contains a double-stranded, circular, supercoiled DNA
genome of approximately 134 kb (19). During AcMNPV infection, the viral genome is
expressed in four different stages - immediate early, early, late and very late -- at which
different genes are transcribed. The very late stage spans from approximately 18 hour
post-infection until cell lysis. Two viral proteins are produced in large quantities during
the very late phase, eventually amounting to -50% of all cellular proteins. These are the
polyhedrin protein, a viral structural protein of 29 kDa, and the p10 gene product, a non-
structural protein of 10 kDa. Both proteins are non-essential for replication and
formation of virus particles (20,21) and therefore have been targeted for use in expression
vectors. In many of the widely used baculovirus expression vectors, the polyhedrin gene
is replaced with the recombinant gene and the strong polyhedrin promoter will drive the
transcription of the foreign gene, expressing the recombinant protein during the very late
phase of the infection (22).
The host cells for the baculovirus, Spodopterafrugiperda (Sf) cells, were
originally derived from pupal ovarian tissue of the fall armyworm (23). Spodoptera
frugiperda IPLB-Sf-21AE (Sf21) cells and a cloned version of this cell line (Sf9) are
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commonly used for the expression system. These cells can be grown either as a
monolayer or in suspension culture at 25 to 28'C in a low protein media containing fetal
bovine serum and antibiotics.
The first step to recombinant protein expression is the construction of the
baculovirus transfer vector containing the gene of interest. The size of the AcMNPV
genome is too large for routine molecular biological manipulations such as restriction
digests and ligation. Instead, the target gene is inserted into a transfer vector (size <10
kb) and the completed plasmid is co-transfected into insect cells along with the AcMNPV
viral DNA. Inside the cell, a complete expression vector is formed via homologous
recombination between the transfer vector and the viral DNA.
Clontech's BacPAK6 system applied a number of modifications to the virus
genome in order to improve the frequency of recombination. As illustrated in Figure 5,
three Bsu36I sites were introduced into the viral DNA. It linearized the genome, which
increased the frequency of recombination in insect cells (24). The Bsu36I digests also
disrupt ORF 1629 gene, a gene essential for viral replication in host cells (25). Infectious
viruses are formed only when a successful recombination takes place between the viral
DNA and the transfer vectors such as pBacPAK8 and pBacPAK9 containing the ORF
1629 gene, giving rise to an intact ORF 1629. On the other hand, recircularized viral
DNA is not viable because it lacks ORF 1629. The Bsu36I digest also eliminates the
polyhedrin promoter from the viral DNA, which is also restored, along with the target
gene, by the recombination with the transfer vector. These features of Clontech's
BacPAK6 system drastically increases the recombination frequency, reducing the need to
screen many viral clones to obtain the desired recombinant virus.
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Once the recombinant virus is produced by co-transfection, the virus is screened
via plaque assay to acquire a pure stock of the virus. The production of clear, well-
defined plaques during the assay demonstrates the viability and high titers of the
recombinant virus. The production of the correct protein by the isolated virus is
confirmed by Western blot analysis of the cell extracts from a small-scale infection.
Then the virus expressing the target protein is amplified for further use. The details of
these steps will be described in the next chapter, Materials and Methods.
The purification of the proteins expressed in the insect cells can be conducted in
one step, using the FLAG epitope. The purification of a FLAG-tagged protein can be
greatly simplified by using an anti- FLAG immunoaffinity column (16). FLAG sequence
is an 8-amino acid peptide (DYKDDDDK), which can be easily detected by
commercially available tools such as anti-FLAG monoclonal antibody and anti-FLAG
immunoaffinity column resin. Production of FLAG-tagged protein is achieved by using
transfer vectors, pSK277 or pSK278, which contain internal sequences coding for FLAG
epitope (16). Because they are derivatives of pBacPAK8 and pBacPAK9, respectively,
they contain all the features of the transfer vectors and can be co-transfected into insect
cells with viral DNA to generate viruses expressing N-terminal FLAG-tagged proteins.
The baculovirus expression system, therefore, is an excellent system for the
purpose of this project. Its capacity to yield a large quantity of the protein via quick and
easy purification procedure will be able to fulfill the demands for the estrogen receptor.
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Chapter II. Materials and Methods
Materials used
The pSV2NeoCMV vector containing hER cDNA was a gift from Dr. Ruth Sager.
The baculovirus expression vectors pBacPAK9 (Clontech) and pSK278 were gifts from
Dr. Sang Seok Koh of the Whitehead Institute. The E.coli strain DH5a [F-,
#80dlacZAM15, recA1, endA1, gyrA96, thi-1, hsdR17 (rK., mK+), supE44, re/A1, deoR,
A(lacZYA- argF) U 169] was used for the production of plasmids. All enzymes were
purchased from New England Biolabs. pGEM plasmid preparation and [14C]Hexene
synthesis were carried out by Dr. Robert Croy.
Subcloning of hER and hER-LBD into baculovirus vector
The hER cDNA was amplified from pSV2NeoCMV-hER (7). Oligomers ALOl
(5'-CGCGGATCCATGACCATGACCCTCCACACCAAA-3') and ALO2 (5'-
CCGCTCGAGTCAGACTGTGGCAGGGAAACCCTC-3') were used as primers for
PCR reaction to obtain full-length hER cDNA. The fragment was double digested with
BamHI and XhoI and inserted into baculovirus expression vectors, pBacPAK9 and
pSK278, between the same sites to give ER and FLAG-ER, respectively. Oligomers
ALO3 (5'-CGCGGATCCATGTCTGCTGGAGACATGAGAGCTGCC-3') and ALO2
were used as primers for PCR reactions to obtain the ligand binding domain (LBD) of
hER. The PCR product was inserted into pBacPAK9 between BamHI and XhoI sites to
give LBD. Similarly, PCR product obtained with oligomers ALO4 (5'-
CGCGGATCCTCTGCTGGAGACATGAGAGCTGCC-3') and ALO2 was inserted into
18
BamHI and XhoI sites of pSK278 to give FLAG-LBD. The positive clones were
confirmed by BamHI/XhoI digestion and the plasmids were isolated using Qiagen
Plasmid Maxi Kit.
Culturing of Sf21 cells
Sf21 cells were cultured in ExCell420 (JRH Biosciences) insect cell media
containing 10% Fetal Bovine Serum, 50 pg/mL Penicillin-Streptomycin (Life
Technologies) and 2.5 pg/mL Fungizone (Life Technologies). The cells were grown at
27'C on 150x25 mm tissue culture plates or in suspension. For suspension cultures,
0.1% of Pluronic-F68 (Sigma) was added to the media.
Isolation of recombinant baculovirus
In order to produce a large quantity of the full-length and the ligand binding
domain of hER protein in insect cells, recombinant baculoviruses expressing the proteins
were constructed. The plasmids coding for ER (pAL3), LBD (pAL4), FLAG-ER (pAL5)
and FLAG-LBD (pAL6) were co-transfected into Sf21 cells along with BacPAK6 viral
DNA BsuI36 digest (Clontech) to produce recombinant viruses. The recombinant viruses
were isolated by plaque assay and the expression of the appropriate proteins was
confirmed by Western blot analysis of the whole cell extract from the Passage One (P1)
virus. The virus was then amplified through subsequent passages in preparation of the
large-scale expression and purification.
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1. Co-transfection
For each construct containing estrogen receptor gene, 0.5 pg of plasmid DNA and
5 pl of BacPAK6 viral DNA were incubated at room temperature with Bacfectin
provided by Clontech to form DNA-lipofectin complexes. The complexes were co-
transfected into exponentially growing Sf21 cells on 6-well plates and the cells were
incubated at 27 0 C. After 72 hours, the media containing the recombinant viruses was
collected.
2. Plaque assay
Densely plated Sf21 cells were infected with co-transfection supernatant at
various dilutions. The cell monolayer was overlaid with low-melting agarose (1% Sea
Plaque agarose from FMC) into which cells can grow. Media was added after the
agarose layer was set and the plates were incubated at 270 C. After 5 days, the cells were
stained with Neutral Red (Life Technologies) and developed overnight. Plaques well
isolated from the surrounding plaques were selected. Four plaques per construct were
picked and placed in media overnight to release the virus from the agarose plug.
3. Passage one and whole cell extract preparation
Sf21 cells were infected with the virus released from the plaques. After 4 days,
the media was collected and the cells were harvested. The media containing Passage one
(P1) virus was stored at 4'C. The whole cell extract (WCE) was prepared by lysing the
cells with lysis buffer (50 mM Tris-Cl pH7.6, 150 mM NaCl, 2 mM EGTA, 1% Nonidet
P-40, 0.25% sodium deoxycholate, 1 mM PMSF, 2 mM benzamidine, 0.6 tM leupeptin,
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2 pM pepstatin A, and 2 tg/mL chymostatin), pelleting out the cell debris and collecting
the resulting supernatant.
4. Western blot analysis
The expression of the appropriate proteins was confirmed by immunoblotting.
Whole cell extracts were separated on SDS-PAGE gels and the proteins were transferred
to nitrocellulose membranes. The membranes were incubated with anti-hER raised
against DNA binding domain (Affinity Bioreagents, Inc. MA 1-3 10), "hinge" region
(StressGen, SRA-1000) or ligand binding domain (StressGen, SRA-10 10) in order to
detect virus expressing proteins with the respective functional regions. WCE from
baculoviruses derived from pAL5 (FLAG-ER) and pAL6 (FLAG-LBD) were blotted
with anti-FLAG antibody (Sigma, F3165) as well, in order to confirm that the FLAG tag
was intact in these proteins. The blots were incubated with anti-mouse IgG-HRP
secondary antibodies. The signals were developed using SuperSignal ECL kit (Pierce)
and were visualized by exposure to film.
5. Passage two preparation
The P1 viruses that expressed the correct proteins were pooled together and the
viruses were amplified. 1.4x 107 cells plated on 150x25 mm plates were infected with 2
mL of P1 virus and incubated at 270 C. After 4 days, the media containing the viruses
(Passage two--P2) were collected and were ready to be used for large-scale infection and
purification of the proteins.
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Expression and purification of FLAG-ER and FLAG-LBD
1. Large scale infection
Sf21 cells grown in suspension to a density of 1.8x10 6 cells/mL were infected
with P2 viruses. 500 mL of cells were harvested and the cell pellet was resuspended in
50 mL of P2 virus. Infection mixture was incubated at room temperature for 1 hour with
occasional swirling. The volume was brought up to 500 mL with fresh media and the cell
culture was grown at 27 'C for 60-66 hours. Cells were harvested and washed with
phosphate-buffered saline. The media, the Passage three (P3) virus, was collected and
stored at 4'C.
2. Cell extract preparation
The harvested cell pellets were resuspended in 7 mL of MTB 100 buffer (50 mM
HEPES-KOH pH 7.3, 100 mM KOAc, 25 mM MgOAc, 5 mM EGTA, 10% glycerol, 1
[tM DTT, 0.01% Nonidet P-40, 1 mM PMSF, 2 mM benzamidine, 0.6 pM leupeptin, 2
pM pepstatin A, and 2 ptg/mL chymostatin) and the cells were lysed by sonication. The
lysate was centrifuged in the ultracentrifuge at 28,000 rpm, 4'C for 3 hours in the SW41
rotor. The resulting supernatant was the cell extract containing the recombinant proteins.
An aliquot of the extract was saved for Western blot analysis.
3. Protein purification
The column with lmL anti-FLAG resin (Sigma, A1205) was equilibrated at 4'C.
The column was washed with 100 mM glycine-HCl pH 3.5 and then with MTB300 buffer
(same as MTB 100, except 300 mM KOAc). The salt concentration of the cell extract
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was adjusted to 300 mM with 5 M KOAc. The cell extracts were loaded onto the column
4 times to maximize the retention of the proteins by the resin. The column was washed
with MTB300 buffer and then with MTB 100 to bring the salt concentration back to 100
mM. The proteins were eluted with MTB 100 buffer containing FLAG peptide (Sigma,
F3290) in eight 1 mL-fractions. The presence of the proteins in each fraction was
monitored by Bradford assay (26) and the fractions containing the proteins were pooled
together. The excess salts, FLAG peptide and buffer were eliminated from the eluate
using Centricons concentrators.
4. Protein quantification
The purified proteins were quantified by performing the Bradford Assay, using
bovine serum albumin as the standard. The purity and the quantity of the purified
proteins were determined by SDS-PAGE analysis. The protein bands were visualized by
Coomassie stain.
Protein expression time course
50 mL of Sf21 cells per time point per protein were seeded on tissue culture plates
at 0.7x106 cells/mL. 2 mL of P2 virus were used to infect 3.5x10 7 cells at room
temperature. The cells were grown at 27'C and were harvested every 6 hours between 36
and 72 hours post-infection for FLAG-ER and every 12 hours between 36 and 72 hours
post-infection for FLAG-LBD. The extracts were prepared as described above and
Western blot analysis was performed with anti-LBD antibodies to detect the protein
expression level at each time point.
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Ligand binding assay
1. Estradiol competition
The purified FLAG-ER and FLAG-LBD proteins were diluted to 2.34 nM with
BSA solution (10 mg/mL) and a stock solution of 100 nM [3H]estradiol (1 mCi/pl, New
England Nuclear) was prepared. Serial dilutions of unlabeled estradiol ranging from 20
ptM to 0.02 ptM were made in 50% DMF. The reactions containing 2.1 nM protein, 5 nM
of [3H]estradiol and varying concentration of unlabeled estradiol in a total reaction
volume of 50 pl were incubated overnight at 4C. Fifty pl of Dextran/charcoal mixture
(0.5% Dextran, 0.5% charcoal in 10 mM Tris pH 7.6) was added to each tube and the
tubes were incubated on ice for 30 minutes with occasional vortexing. The tubes were
centrifuged at 4'C for 5 minutes and 75 1tl of supernatant was counted in 5 mL of
scintillation fluid.
2. Drug binding assay
In lieu of unlabeled estradiol, dilutions of Heptene (for FLAG-LBD only),
Hexene and Amine Mustard (AM) were added to the competition reaction described
above. From 1 mM stock solution of each drug, dilutions ranging from 20 pM to 0.1 IM
were prepared for the reaction. The concentration of the test compound necessary to
reduce receptor-bound radioactivity by 50%, the concentration at the inflection point, was
determined from the plot of drug concentration vs. [3H]estradiol CPM. The relative
binding affinity (RBA) was determined by multiplying the molar ratio of the inflection
point of estradiol and the test compound by 100 (5).
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Gel mobility shift assay
1. Target preparation
Oligonucleotides Cl (5'-TTCTGGCCTCCTCT-3') and C2 (5'-
CGCTCGAGAGGAGGCCAGAATTCGGA-3') were 5' phosphorylated with [y- P]
ATP (New England Nuclear) to give radiolabeled target DNA. Twenty pmol of each
oligonucleotide were incubated at 37'C for 1 hour with 40 pCi [y- P] ATP, T4
polynucleotide kinase and lOx kinase buffer. The Cl oligomer previously modified with
one molecule of Heptene, called Hep 1, was phosphorylated similarly. Free [32P] ATP
was eliminated by G25 columns at the completion of the reaction.
Labeled Cl was annealed with unlabeled C2, and unlabeled Cl was annealed with
labeled C2 to give duplexes with one labeled strand and one unlabeled strand. The
annealing reactions were carried out by heating to 80'C and cooling to room temperature
overnight. The duplexes were called ClD and C2D respectively. Also, the duplex of
Hep 1 with unlabeled C2 was called ClD-Hep 1. Cl D-Hep 1 was prepared by incubating at
4'C in 0.5 M NaCl and 25 mM Tris pH 8.0 overnight.
2. Drug reaction
Both ClD and C2D were allowed to react with drugs Heptene or Phenylindole (PI)
to give DNA with drug lesions. Ten pmol of each duplex DNA were incubated with
Heptene or PI at 37'C for 12-16 hours. The drug-adducted DNA was isolated by phenol-
chloroform extraction followed by ethanol precipitation. The presence of the drug-
adducted DNA duplex was confirmed by running a 16% denaturing gel and visualizing it
on phosphorimager screen.
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3. GMSA
Binding reaction of the protein to adducted DNA was performed in DNA binding
buffer (15 mM Tris pH 7.9, 80 mM KCl, 4 mM DTT, 0.2 mM EDTA and 10% glycerol)
with 10 pg of BSA and 1 pg of p(dIdC) carrier DNA as specified in Nardulli et al. (27).
Twenty-five ng of FLAG-LBD and DNA duplex displaying approximately 15,000 CPM
counts were added to the reaction. The reaction mixtures were incubated at 37'C for 20
min. The results were visualized by on a native, low salt, 5% polyacrylamide gel.
Protein-drug-DNA association mechanism
Reactions contained 15 pg of BSA, Ipg of pGEM (0.5 pmol), 0.15, 0.3, 0.45 or
0.6 ptg of FLAG-LBD protein (4.5, 9,13.5, 18 pmol, respectively) in IM TE pH 8.0.
[ 4 C]Hexene (specific activity of 53 mCi/mmol) was added to a final concentration of
200 pM. The reactions were incubated at 37'C for ihour. Proteins in the reactions were
eliminated by phenol/chloroform extractions and the DNA was recovered by ethanol
precipitation in the presence of 6 pg of glycogen. The DNA pellet was resuspended in 10
pl of TE pH 8.0 and half of the recovered DNA was separated on a 0.8% agarose gel.
After visualizing the bands with UV, the gel was dried and exposed on phosphorimager
screen for 36 hours for imaging.
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Chapter III. Results
Subcloning of hER and hER-LBD into baculovirus vector
The subeloning of full-length and ligand binding domain of the hER into
baculovirus expression vectors was carried out as illustrated in Figure 6. The PCR
reaction with pSVNeoCMV as the template and ALOl and ALO2 as the primers gave a
1.8 kb fragment with a flanking BamHI restriction site at the 5' end and a XhoI
restriction site at the 3' end. The fragment was double digested with BamHI/XhoI and
ligated into BamHI/XhoI-digested pBacPAK9 and pSK278 baculovirus expression
vectors. The 7.3 kb plasmids that resulted from the reaction were designated pAL3 and
pAL5, respectively, and served as the construct for the ER and FLAG-ER baculoviruses,
respectively.
The amino acid residues 282 to 595 code for the "hinge" region and the ligand
binding region of the estrogen receptor protein (28). This region was subcloned into the
baculovirus expression vectors to produce the ligand binding domain (LDB) of the
estrogen receptor. The PCR reaction with pSVNeoCMV, ALO3 and ALO2 gave a 0.94
kb fragment also with BamHI and XhoL sites. Because the ligand binding domain is
located near the C-terminus of hER, it does not contain an internal start codon (ATG)
from which the protein can be translated. The codon was included in the primer, ALO3,
so that the resulting PCR product would have a start codon immediately following the
BamHI restriction site. The PCR product was inserted into pBacPAK9 as above and the
6.5 kb plasmid construct for LBD was named pAL4.
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The PCR reaction with pSVNeoCMV, ALO4 and ALO2 yielded a 0.94 kb
fragment that was used for the subcloning of FLAG-LBD. Because pSK278, a
baculovirus expression vector with a built-in FLAG sequence, already contained a start
codon (16), the PCR primer did not need to contain a separate start codon. ALO4 and
ALO2 amplified the ligand binding domain and created BamHI and XhoI sites at the 5'
and 3' ends, respectively. Restriction digest and ligation into pSK287 yielded a 6.5 kb
plasmid expressing FLAG-LBD and it was designated pAL6.
Generation of baculovirus expressing ER and LBD
The recombinant viruses expressing ER, LBD, FLAG-ER and FLAG-LBD were
produced by co-transfecting BacPAK6 with pAL3, pAL4, pAL5 and pAL6, respectively.
Plaque pick assay enabled the visualization of the recombinant viruses' infection of Sf21
cells and isolation of the viruses. All viruses gave numerous well-defined plaques at all
dilutions of the co-transfection supernatant. Four plaques for each virus were picked
from wells infected with 10-3 or 104 dilutions of the cotransfection supernatant, because
those dilutions gave most well-isolated plaques.
The viruses expressing the correct proteins were identified by Western blot
analysis. The WCE of the cells expressing ER and FLAG-ER were blotted against anti-
ER (raised against the DNA binding domain) antibody. FLAG-ER was blotted against
anti-FLAG antibody to check for the presence of the FLAG tag. None of the 4 clones of
ER displayed signals on the anti-ER blot (data not shown). The clones of FLAG-ER
expressed the 67 kDa full-length protein (Figure 7A). Several smaller bands also
appeared on the blot, recognized by both anti-ER and anti-LBD antibodies. These were
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truncated forms of FLAG-ER containing the intact FLAG-tag, which is at the N-terminal
end of the protein, and the DNA binding domain, which is in the front half of the protein.
The P1 virus for FLAG-ER was pooled and was named ALBV1. The WCE from ER-
expressing cells were blotted against anti-ER (anti-DNA binding domain) antibody. The
Western analysis gave no signals for any of the four clones (data not shown). The
production of the recombinant virus for ER was attempted again, starting from
subcloning of the plasmid construct. The yet-to-be-confirmed recombinant virus was
named ALBV3.
The WCE of the cells expressing LBD and FLAG-LBD were blotted against anti-
ER (raised against LBD or the "hinge" region) antibody. FLAG-LBD extracts were also
blotted against anti-FLAG antibody. The clones of FLAG-LBD expressed the 33 kDa
protein with the intact FLAG tag. Similarly, the clones of LBD yielded the 33 kDa
protein (Figure 7B). The Western blot analysis showed that the FLAG-LBD protein was
slightly larger than LBD due to the 8 amino acid FLAG tag. FLAG-LBD and LBD
viruses were named ALBV2 and ALBV4, respectively.
Expression and purification of FLAG-ER and FLAG-LBD
The full-length, FLAG-tagged ER protein was purified using the anti-FLAG
affinity resin. One major band and two minor bands co-eluted near 67 kDa (Figure 8).
The major band was approximately 80% of the total proteins eluted. The truncated
proteins which contained the intact FLAG-tag may have co-purified with the full-length
FLAG-ER, but would have been removed in the concentration step where Centricon-50
eliminated everything whose molecular weight was smaller than 50 kDa. Using the one-
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step purification procedure, approximately 30 pg of the FLAG-ER was purified from 500
mL of Sf21 cells.
In order to obtain the homogeneous FLAG-ER, the baculovirus (ALBV 1) was re-
isolated by repeating the plaque assay, but the contaminant bands could not be
eliminated. There have been reports suggesting that hER can be posttanslationally
phosphorylated in Sf9 and MCF-7 cells (29,30). It is possible that one of the
contaminating bands was the phosphorylated form of ER. Also, the extraneous bands
may be the broken-down forms of FLAG-ER, if the protein had become unstable during
the purification process.
FLAG-LBD was also purified by the one-step procedure. The 33 kDa protein was
approximately 70% homogeneous with one contaminant protein roughly 67 kDa in size
(Figure 8). A 1 L Sf21 culture yielded 30-45 pg of the FLAG-LBD.
Protein expression time course
The time course protein expression was conducted in order to optimize the protein
expression procedure. The Western blot analysis using anti-LBD antibody indicated that
the highest FLAG-ER expression was 54-hour post-infection (Figure 9A). The protein
expression level had dropped off by 62-hour, the infection time designated in the original
protocol.
The expression level of FLAG-LBD peaked at 60-hour post-infection and
decreased afterwards (Figure 9B). This coincided with the original protocol, which
specified between 60 and 66 hour infection at 270 C. For the subsequent protein
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expression attempts, the infection times were adjusted according to the findings from this
experiment.
Competitive binding of FLAG-LBD to estradiol and drugs
The ability of the FLAG-LBD to bind to estradiol, the natural ligand of the ER,
was examined. The amount of radiolabeled estradiol bound to FLAG-LBD as a function
of unlabeled estradiol concentration yielded a sigmoidal curve indicating that the FLAG-
LBD is functional in binding its natural ligand (Figure 10 A). The recombinant protein
displayed the inflection point of approximately 10 nM, which was comparable to the
inflection point reported in the previous study (5).
Upon confirming that the recombinant protein actively bound the ligand, its
ability to bind to different drugs was examined. The FLAG-LBD showed binding to both
Heptene and Hexene (Figure 1GB and 1 OC), although the binding was not as strong as
that of estradiol. The plot of radiolabeled estradiol amount in relation to the drug
concentration showed a sigmoidal curve for both drugs, but the curve was shifted to the
right (inflection point = 34.1 nM) compared to the curve for estradiol indicating that the
binding of the drugs was weaker than that of estradiol. The relative binding affinity
(RBA) of Hexene to estradiol was approximately 39. The RBA of Heptene could not be
easily compared, because different batches of purified protein and different lots of
tritiated estradiol were used for the two assays. However, similar assays done using calf
uterus whole cell extract containing estrogen receptor proteins showed similar RBAs for
the two compounds (Croy and Essigmann, unpublished data).
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The assay using AM showed no association between the FLAG-LBD and the
compound (Figure 1 OB). This was expected, since the compound lacks the hormone
moiety, which would interact with the ligand binding domain.
Competitive binding of FLAG-ER to estradiol and drugs
The competitive binding of FLAG-ER to estradiol and the drugs showed very
similar results to those of FLAG-LBD. The amount of radiolabeled estradiol bound to
the protein showed a sigmoidal curve, indicating that the protein actively bound the
ligand (Figure 11 A). Similarly, in the reaction where Hexene was competing against the
labeled estradiol for binding to the protein showed binding, although the affinity was not
as high as that of estradiol (Figure 1 IB). As it was for FLAG-LBD, the reaction with
AM showed no competition (Figure 11 B).
Gel shift mobility assay
A gel mobility shift assay (GMSA) was performed to assess the ability of the
FLAG-LBD to interact with DNA modified with different drugs. In the presence of
FLAG-LBD and drug-damaged DNA, the protein-DNA complexes via drug were formed
and band shifts were observed (Figure 12 lanes 3, 4, 5, 8 and 9). The lanes with DNA
alone or unmodified DNA with the protein, however, did not show the slow-moving band
(Figure 12 lanes 1, 2, 6 and 7). In both ClD and C2D complexes, duplexes modified with
Heptene had stronger affinity towards FLAG-LBD than did those modified with PI
(Figure 12 lanes 3 and 4, 8 and 9). Also, a much stronger association between the protein
32
and the DNA was observed when there were multiple drug adducts on the DNA,
compared to the mono-adducted DNA (Figure 12 lanes 4 and 5).
This assay confirmed that the recombinant protein was functional in binding not
only free drugs, but also in forming complexes with DNA modified by the drugs.
Protein-drug-DNA association mechanism
This experiment was performed in order to investigate the kinetics of the protein-
drug-DNA formation. As shown in Figure 13, two different paths of association are
available when the radiolabeled drug ([14C]Hexene) is added to a reaction containing
DNA (pGEM) and the protein (FLAG-LBD)-the drug may react with the DNA first (B)
or it may bind to the protein first (D). The formation of the protein-drug-DNA complex
(C) from B has been demonstrated with GMSA, but it has not been shown if the same
complex can be formed from D.
In this reaction, the proteins were removed from the reaction mixture by
phenol/chloroform extraction and the remaining DNA was resolved on an agarose gel and
was visualized with UV. The phosphorimager analysis of the same gel showed the
radiolabeled drugs adducted to the DNA.
The UV visualization of the plasmids reacted with the drug in the presence of
different amounts of FLAG-LBD showed similar intensity bands (Figure 14A).
However, the phosphorimager analysis of the same gel showed a decrease in the I4C
signals as the amount of the protein added to the reactions increased. This indicates that
as the protein concentration in the reaction increases, the association between the protein
and the drug probably occurs more frequently than that between the drug and the DNA.
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This path does not completely take over, shown by the existence of the bands in the
phosphorimage up to the point where the ratio between the protein and the drug adducts
was 9:1 (Figure 14B lanes 2 to 5). However, when the ratio of the protein to the drug
adduct was approximately 1.5:1 (using the estimation of 6 drug adducts per pGEM
plasmid (Croy and Essigmann, unpublished data)), a significant amount the drug reacted
with the plasmid (Figure 14B, lane 2). The faint bands above the main bands in lanes 1
and 2 of both the UV visualization and the phosphorimage were probably the nicked form
of the plasmid, formed by the reaction with the drug.
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Chapter IV. Discussion
This study describes the expression and the purification of the human estrogen
receptor (hER) and the ligand binding domain of the hER using the baculovirus
expression system. In order to investigate the mechanism and the optimization of the
estrogen receptor-selective genotoxins, the production of a large quantity of pure proteins
was required. The use of the baculovirus system allowed the expression of the
recombinant proteins in insect cells, thereby eliminating the need to work with the cell
extracts prepared from animal organs containing estrogen receptors.
The plasmid constructs containing hER cDNA in baculovirus expression vectors,
the recombinant viruses derived from the constructs and the proteins expressed by the
viruses are listed in Table 1. It was demonstrated that a one-step purification yielded
proteins competent to bind the natural ligand, estradiol, as well as drugs containing
estradiol moiety. 30 to 45p.g of FLAG-LBD was purified from 1 L of Sf21 cells and
approximately 30pg of FLAG-ER was purified from 500mL of Sf21 cells.
Purity of the Proteins
Much of the purity and the yield of the recombinant proteins seemed to depend on
the status of the Sf21 cell culture at the time of infections. The same amount of cells at
the same point in their growth curves infected with the same ALBV2 virus yielded
different amount and purity of FLAG-LBD protein. Therefore, it was crucial that the
Sf21 cells were healthy -- growing rapidly and have normal morphology -- at the time of
the infection and that the cell culture was replaced with cells from the frozen stock at a
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regular interval. It has been suggested that high passage number of cells decreased virus
production (18).
A few observations were made regarding the purification of the FLAG-ER and
FLAG-LBD. FLAG-ER co-eluted with two contaminating bands similar to FLAG-ER
in size. If one of the bands was the phosphorylated form of the protein, the treatment
with phosphotases would collapse that band, increasing the purity of the protein. On the
other hand, if the contaminating bands were broken-down form of the protein because the
protein was not stable enough during the purification, it has been speculated that eluting
the protein in the presence of a trace amount of estradiol may enhance the stability. This,
however, would not be an ideal method of the protein purification for the purpose of this
study, since the examining the interaction between the protein and the drugs is an
essential aspect of the study. The protein purified with estradiol, and therefore is bound
to the ligand, is less likely to interact with the drugs, given the protein's higher affinity
towards estradiol than that towards the drugs being studied. Because of the possibility
that an incompetent recombinant virus was the cause of the impure protein, co-
transfection of pAL5 and isolation of new virus are being repeated.
FLAG-LBD also co-eluted with a protein 66kDa in size. The Western blot
analysis of the cell extract just prior to the purification showed no corresponding signal at
66kDa, indicating that the contaminating band does not contain a portion recognized by
anti-ER antibodies and is not related to ER protein. It is possible that the protein is a
cellular protein that contains amino acid sequence recognizable by anti-FLAG affinity
resin.
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Baculovirus expressing ER
The failure to produce baculovirus that expressed untagged ER may be due to the
plasmid DNA from which the virus was derived. The fact that the co-transfection
supernatant gave many clear plaques and yet all four plaques isolated failed to express the
correct protein suggests that the plasmid clone selected for the co-transfection was the
source of error. It is possible that the selected clone contained a mutation, which was not
detected by the restriction enzyme analysis following the miniprep of the clones, caused
the expression of a different protein or no expression at all. The possibility of ER being
toxic or unstable to be expressed in the cells were excluded, since there have been a
number of purification of ER via baculovirus system reported in the literature (29,31).
Activity of the recombinant proteins
Some observations about the activity and the overall quality of the purified
recombinant proteins could be made from the binding curves of the proteins. First, the
binding curves for the FLAG-ER and FLAG-LBD with estradiol (Figures 1OA and 11 A)
both show sigmoidal curves, indicating that both proteins bind to their natural ligand.
However, there was approximately 4-fold difference in the maximum amount of the
tritiated estradiol bound to FLAG-ER and to FLAG-LBD, although the same number of
receptors, calculated from the protein concentrations, was used for both sets. This
suggests that the purification of FLAG-LBD was more successful than that of FLAG-ER
and that the amount of the active FLAG-ER in the final purification product was less than
previously thought. It is likely that most of the protein of the major band in Figure 8 was
contamination or inactive FLAG-ER. Therefore, it will be beneficial to attempt the
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purification of FLAG-ER by remaking the recombinant baculovirus, starting from co-
transfection. Further characterization with the more pure FLAG-ER would be very
informative.
Secondly, although the purity of the two proteins differed greatly, the quality of
the active proteins seems to be very similar. The two binding curves for estradiol in
Figure 1 OA and 11 A, when scaled to account for differing y-value range, overlap almost
completely (Figure 15A). Despite the differences in the absolute binding amount of
estradiol, the two proteins' bindings towards the ligand at different ligand concentration
were similar. The curves overlapped almost completely and they have almost the same
inflection point at ~1OnM (FLAG-ER: 11.7nM, FLAG-LBD: 10.9nM), indicating that the
amount of unlabeled estradiol need to occupy half the active proteins is very similar. The
same phenomenon was found in the binding curves against Hexene. Despite the
differences in the absolute CPM values -- in other words, the amount of the labeled
estradiol bound to the proteins -- the curves, once again, almost overlapped (Figure 15B)
and they showed similar inflection points at -45nM (FLAG-ER: 41.2nM, FLAG-LBD:
34. lnM). These findings suggest that although one purification process was more
successful than the other was, both preparations contained active proteins and that the
two proteins display same binding affinity toward the ligands.
Lastly, the percent activity of the FLAG-LBD purified was calculated using the
scintillation counts of the tritiated estradiol when the protein was reacted with the labeled
estradiol only. The calculation was carried out using the obtained CPM value, the protein
and the labeled estradiol amounts and taking into account the specific activity of the
labeled estradiol (72Ci/mmol) and the counting efficiency of the scintillation counter
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(-40%). It was estimated that approximately 89% of the proteins added to the reaction
were bound to estradiol, therefore presumed active. However, the accuracy of this
estimation was limited to the accuracy of the protein concentration concluded from the
gel quantification as well as the purity and the activity of the tritiated estradiol.
Formation of the protein-drug-DNA complex
It had been demonstrated with the gel mobility shift assay discussed earlier
chapter that when drug-damaged DNA is present, FLAG-LBD binds to the complex via
the drug. However for an in vivo application, DNA and the estrogen receptor protein are
already present in the cell and the drug is added. This experiment was performed to
simulate the situation in the cell by adding the drug into a reaction where the DNA and
the protein are already present. As mentioned in the Results chapter of this report, the
drug seems to associate with the protein more often, especially when more protein is
added to the reaction. It was not possible to deduce from this experiment whether the
protein-drug complex can still bind to DNA, since all three states-B, C, and E in Figure
13-- would appear the same on the phosphorimager analysis. Thus, major bands in the
phosophorimage can be either the results of B, E or the combination of the two. In either
scenario, it indicates that the three-component complex can be formed if the ratio of the
protein to the drug adducts is approximately 1.5:1.
Conclusion and Significance of Results
This study explored the one-step purification of recombinant proteins, FLAG-ER
and FLAG-LBD. The proteins were purified to 70% homogeneity (in the case of FLAG-
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LBD) and in large quantities. The proteins displayed binding to estradiol and to the free
drugs containing an estradiol moiety and showed high activity. The FLAG-LBD protein
also bound to drugs adducted to DNA, demonstrating that the protein-drug-DNA
complex, whose formation is vital to the efficacy of estrogen receptor selective
genotoxins, can be assembled. Also, it was shown that such complexes still form when
the drugs are free to bind either the DNA or the protein first.
The production of the purified ER proteins also provides material for many other
aspects of the studies pertaining to the estrogen receptor selective genotoxins. For
example, purified proteins are a vital component of the repair assay being developed in
the lab, which investigates the efficiency of the repair mechanisms towards DNA treated
with the tumor selective drugs in the presence of the estrogen receptor.
Future directions
The results of this studies gave rise to many questions that should be further
investigated. First, as mentioned earlier in this section, re-production of FLAG-ER virus
in order to obtain proteins of higher purity and activity is necessary. Although according
to the scheme of tumor-selective genotoxins, the region of the protein in direct contact
with the drug and the DNA is the ligand binding domain and the formation of the protein-
drug-DNA complex is demonstrated using the FLAG-LBD, the validity of the system
cannot be assumed. The full-length estrogen receptor is approximately twice the size of
the ligand binding domain purified during this study and the added bulk of the protein
may have a slightly different interaction with the other components. Also, the DNA
binding domain, the region missing from the ligand binding domain, may affect the
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interactions differently. Therefore, it is essential that the full-length protein of good
quality is obtained and further characterized.
Also, the kinetics of the protein-drug-DNA complex association should be studied
more in depth. The formation of the complex is vital to the efficacy of the estrogen
receptor selective genotoxins and it is important to understand the nature of the
components. To follow up on the initial findings presented in this work, experiments
elucidating the association kinetics of the three-component complex when the protein is
already bound to the drug needs to be performed. Such information will be essential for
the optimization of the drug dosing.
Another study that would give valuable insights into the molecular mechanism of
the drugs is mutational studies of the protein. Different mutant forms of the estrogen
receptor protein can be made and used to investigate the interaction between the protein
and the drug. In order to achieve this, the residues of the proteins, which are suspected to
be important in binding the ligands should be mutated by site-directed mutagenesis.
Altering these residues could affect the protein's binding affinity towards the natural
ligand and examining the mutations' effects on the drug-binding capability will improve
our understanding of the interaction between the protein and the drugs on the molecular
level.
There have been a number of studies with mutant estrogen receptor reported in
the literature (30,32,33). Of these, two mutant proteins seem to be promising candidates.
Glu353Gln mutant showed a 9-fold decrease in binding affinity towards estradiol (33)
and His524Ala mutant displayed a 12-fold decrease in biding affinity towards the ligand
(32). They were two of the three amino acids identified as residues important in binding
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estradiol according to crystallography studies (12,13). Both form hydrogen bonds to the
hormone, holding it diagonally across the cavity of the protein.
The construction of the plasmid DNA containing the mutated hER gene followed
by the expression and the purification of the mutant proteins in the baculovirus
expression system will provide these proteins to be used in the investigation.
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Figure 1. Design of programmable anti-cancer drugs
This is the underlying scheme of the design of the tumor-specific drug. The box inset shows the
basic design of the drug which consists of two domains. The "warhead" domain reacts with the DNA,
forming an adduct. The protein recognition domain is derived from the ligand of the protein
abundant in the cancer cells. In a cancer cell, the lesion formed by the drug would also bind the
tumor specific protein, blocking the damaged site from the DNA repair enzymes. This complex
would be highly toxic to the cell. However, in a normal cell where such protein is not expressed,
the drug adduct would be readily repaired, showing no toxicity.
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Figure 2. Chemical structures of estradiol and the drugs used in this study
All drugs are composed of the DNA binding domain, a nitrogen mustard, and the
protein recognition domain. The protein binding domain is either an estradiol or
otherhormone- like moiety. A. Estradiol, the natural ligand of the estrogen receptor
protein. B. PI-C6NC2, the protein recognition domain is a phenylindole. C.
E2-C6NC2, same as B except the phenylindole is replaced with estradiol. D.
E2-Heptene, the alkene derivative of the 7-carbon linker. E. E2-Hexene, the alkene
derivative of C. * indicates the position of the 1 4C label in [I 4C]Hexene. F. Amine
mustard (AM), the control compound lacking the protein recognition domain and the
carbon linker leading up to the amine.
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Figure 3. Crystal structure of hER-LBD and the ligand binding pocket
A. The ribbon representation of the ligand binding domain of the estrogen receptor. The
structure shown is a homodimer of the protein containing 2 molecules of estradiol The
ligand is represented as red space-fill model. The structure is rendered in Rasmol from the
crystallography data published by the Sigler group (12). B. The ligand binding pocket of
the hER. The interactions between estradiol and the residues of the protein are illustrated.
The D-ring hydroxyl group of estradiol forms a hydrogen bond with His524. The phenyl
hydroxyl group forms hydrogen bonds with Arg394 via a water molecule and directly with
Glu353 of the protein. The figure was borrowed from Tanenbaum, et al. (12).
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Model of (E2-C 6NC2)- Modified IDNA:hER LBD
lkr
Figure 4. Model of E2-C6NC2-modified DNA bound to hER-LBD
The structure of the DNA modified by the drug, E2-C6NC2, was docked into the
binding pocket of the hER-LBD. The structure of the protein used was solved by the
Sigler group (12). The model was obtained by performing a energy-minimization
in water using molecular modeling program, Insightil. The protein backbone is
rendered as ribbon, the drug molecule is shown as a ball-and-stick figure and the
DNA helix is represented as sticks.
52
Bsu361-linearized BacPAK6 DNA
* * *
Transfer Vector
* Flanking sequence
pp Polyhedrin promoter
ORF 1629
Foreign Gene
XK Homologous recombination
* Bsu361 restriction site
Figure 5. AcMNPV genome and co-transfection scheme
The gene of interest is inserted into the baculovirus transfer vector (pBacPAK8/9,
pSK277/278) containing the intact ORF 629 gene, polyhedrin promoter and the
flanking sequences. The plasmid is co-transfected with Bsu361-digested AcMNPV
viral DNA (BacPAK6, Clontech). Homologous recombination following the co-
transfection into Sf21 cells restores the ORFI 629 and inserts the polyhedrin promoter
and the foreign gene, producing a viable virus. The genes of interest for this study
were hER and the ligand binding domain of hER. Figure was adopted from
Merrington, et al. (18).
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Figure 6. Cloning scheme of ER and LBD in baculovirus expression vectors
A PCR reaction with primers ALO1 (6) and ALO2(@) gave the full-length estrogen receptor (ER) gene (1.8 kb).
The fragment was ligated into the baculovirus expression vectors pBacPAK9 and pSK278 to give pAL3 and pAL,
respectively. pAL3 was the construct for the un-tagged ER and pAL5 was the construct for FLAG-ER. Similarly,
PCR reaction with ALO3(@) and ALO2 gave the ligand binding domain (LBD) fragment (0.94 kb) containing the
start codon (ATG). The fragment in pBacPAK9 yielded pAL4 which was the construct for the un-tagged LBD.
The LBD fragment (0.94 kb) produced by the PCR reaction with ALO4( @) and ALO2 was inserted into pSK278 to
give pAL6, the construct for FLAG-LBD.
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Figure 7. Western blot analysis of the recombinant proteins
A. The whole cell extract of one of the clones (clone #2) expressing FLAG-ER was resolved
on a SDS-PAGE gel. It was blotted against the anti-ER antibody raised against the DNA
binding domain (lane 1) and against the anti-FLAG antibody (lane 2). The lines indicate the
position of the molecular marker standards and the arrow indicates the 67 kDa FLAG-ER.
B. The whole cell extracts of the cells expressing LBD (lanes 1 and 3) and FLAG-LBD (lanes 2,
4 and 5) were separated on a SDS-PAGE gel side by side. They were blotted against the anti-ER
antibody raised against the ligand binding domain (lanes I and 2) and against the hinge
region (lanes3 and 4). FLAG-LBD whole cell extract was also blotted against the anti-FLAG
antibody (lane 5). The lines indicate the positions of the molecular weight standards.
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Figure 8. Purified FLAG-ER and FLAG-LBD
The purified proteins were evaluated by SDS-PAGE analysis. The protein bands were
visualized by Coomassie staining. Lanes 1 and 2 were FLAG-ER and lanes 3 and 4 were
FLAG-LBD. The numbers above the panel were the amount of the desired proteins in
each lane, estimated by comparing to BSA solutions of known concentrations. The
numbers on the right show the molecular weight marker sizes. The arrows on the left
indicate the positions of the proteins, where the upper arrow points to FLAG-ER and
the lower to FLAG-LBD.
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Figure 9. Time course expression of the recombinant proteins
The Western blots of the FLAG-ER (Panel A) and the FLAG-LBD (Panel B) are shown above.
The numbers above the panels indicate the infection time in hours. The cells harvested
at the designated time post-infection were made into whole cell extracts and the extracts
were resolved on SDS-PAGE gels. They were blotted against the anti-ER (raised against LBD)
antibody. The lines represent the position of the molecular weight standards and the arrows
denote the FLAG-ER and FLAG-LBD proteins.
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Figure 10. FLAG-LBD competition assays
The binding of different ligands to the FLAG-LBD is shown. The amount of radiolabeled
estradiol bound to the protein was plotted as a function of unlabeled ligand
concentration. The competing ligand was unlabeled estradiol (A), Hexene (B, closed
circle), AM (B, closed triangle) or Heptene (C).
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Figure 11. FLAG-ER competition assays
The binding of different ligands to the FLAG-ER is shown. The amount of radiolabeled
estradiol bound to the protein was plotted as a function of unlabeled ligand
concentration. The competing ligand was unlabeled estradiol (A), Hexene (B, closed
circle), or AM (B, closed triangle).
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Figure 12. Gel shift mobility assay
The association of the protein and the DNA duplex via estrogen receptor selective
drugs was demonstrated. The DNA duplex with radiolabeled Cl oligo (Cl D) was
used for lanes 1 through 5 and DNA duplex with radiolabeled C2 oligo (C2D) was
used for lanes 6 through 9. Lanes 1 and 6 were negative controls containing only
DNA duplexes whereas lanes 2 and 7 were controls with DNA duplex and FLAG-LBD
protein. Phenylindole (PI) was added to the reactions in lanes 3 and 8. For
Heptene (Hep), + indicates Heptene monoadduct on the DNA (lane 5) and ++
represents multiple adducts of Heptene formed on DNA duplex es (lanes 4 and 9). The
arrow denotes the shifted bands representing the DNA-drug-protein complexes.
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Figure 13. Possible association kinetics of the protein-drug-DNA complex
The possible pathways of interactions among FLAG-LBD, ["C]Hexene and pGEM
are shown. It is shown that the protein binds to the drug when the drug is already
bound to the plasmid (B to C), but it is not known if the drug is capable of binding
the plasmid after it has associated with the protein (D to E). Also, it is not known
if the drug associates with the protein or the DNA preferentially.
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Figure 14. Association kinetics of the protein-drug-DNA complex
The association reaction carried out with different amount of FLAG-LBD protein was
resolved on a 0.8% agarose gel. The plasmid DNA is visualized with UV light (A) and
the [14C]Hexene adducted to the DNA was visualized by phosphorimager analysis (B).
The amount of protein in each lane was 0, 0.15, 0.3, 0.45 and 0.6 pg, which was 0,
1.5, 3, 4.5, 6 fold of the number of the drug adducts estimated to be in each reaction.
The phosphorimager screen was exposed for 36 hours.
65
Ablo duo am* *O A**
Figure 15
A.
* II III IhEj
* FLAG-ER
* FLAG-LBD
11111 liii Mliii I I I I 11111 ~I
1 10 100 1000
Estradiol Concentration (nM)
6000
-5000
-4000 0
-3000
CO)
-2000
- 1000
0
66
0
0-
-
CU
1300-
1200-
1100-
1000-
900 -
800 -
700 -
600 -
500-
-.
I I I I I  I I I I I 1 11 I I I
Figure 15
B.
10 100
Hexene Concentration (nM)
-5000
4000 .
-- o
3000 U
-2000 ..
-1000
-- g-
1000
Figure 15. Comparison of FLAG-ER and FLAG-LBD's ligand binding capacity
A. Figure 1 OA and Figure 11 A are overlapped on a double y-axis graph to show the
resemblance of the two curves indicating the ability to bind estradiol. The left
y-axis is FLAG-ER and the right y-axis is FLAG-LBD. Although the span of the
[3H]Estradiol CPM values are different, the shape and the inflection points
are almost identical (Inflection point of FLAG-ER: 11.7 nM and of FLAG-LBD: 10.9 nM).
B. Overlap of Figure 1 OB and Figure 11 B. As in panel A, these curves compare the
two proteins' binding capacity for Hexene (Inflection point of FLAG-ER: 41.2 nM and
of FLAG-LBD: 34.1 nM)
67
1100
1000
-
C')
w
900
800
700
600
500
400
TABLES
Protein
Name Size (kDa)
FLAG-ER
FLAG-LBD
ER
LBD
67
33
67
33
Baculovirus
ALBV1
ALBV2
ALBV3
ALBV4
Name Size (kb)
pAL5
pAL6
pAL3
pAL4
7.3
6.5
7.3
6.5
Table 1. Plasmid and baculovirus used for protein expression
The names and the sizes of the plasmids from which the baculoviruses were
derived are listed. Also the names and the sizes of the proteins expressed by
the baculoviruses are listed.
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Plasmid
